Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DTIL

Precision Biosciences Inc

Mar 27 • 04:00PM ET

4.54

Dollar change +0.01
Percentage change 0.22	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT SGMO VRTX BLUE ALLO CLLS ADAP IBRX

| Held by: VTI VXF IWC DFAT XDNA DFAS

Scroll to Statements

Index	-	P/E	2.40	EPS (ttm)	1.89	Insider Own	14.84%	Shs Outstand	8.20M	Perf Week	-15.30%
Market Cap	47.59M	Forward P/E	-	EPS next Y	-5.44	Insider Trans	-3.44%	Shs Float	3.46M	Perf Month	-17.60%
Income	7.17M	PEG	-	EPS next Q	-1.53	Inst Own	95.38%	Short Float	17.87%	Perf Quarter	0.89%
Sales	68.70M	P/S	0.69	EPS this Y	-641.67%	Inst Trans	18.86%	Short Ratio	1.24	Perf Half Y	-50.60%
Book/sh	6.87	P/B	0.66	EPS next Y	3.49%	ROA	4.84%	Short Interest	0.62M	Perf Year	-61.53%
Cash/sh	8.23	P/C	0.55	EPS next 5Y	-	ROE	19.05%	52W Range	3.61 - 15.97	Perf YTD	19.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	8.42%	52W High	-71.57%	Beta	1.62
Dividend TTM	-	Quick Ratio	6.34	Sales past 5Y	88.36%	Gross Margin	93.34%	52W Low	25.76%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	6.34	EPS Y/Y TTM	110.55%	Oper. Margin	-38.08%	RSI (14)	37.33	Volatility	8.79% 6.82%
Employees	108	Debt/Eq	0.53	Sales Y/Y TTM	40.98%	Profit Margin	10.43%	Recom	1.00	Target Price	35.75
Option/Short	No / Yes	LT Debt/Eq	0.51	EPS Q/Q	45.38%	Payout	0.00%	Rel Volume	0.13	Prev Close	4.53
Sales Surprise	-85.03%	EPS Surprise	1.44%	Sales Q/Q	-90.93%	Earnings	Mar 26 BMO	Avg Volume	500.62K	Price	4.54
SMA20	-10.95%	SMA50	-11.23%	SMA200	-40.49%	Trades		Volume	65,977	Change	0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$34
Apr-30-24	Initiated	Guggenheim	Buy	$19
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$7
Jun-09-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-27-20	Resumed	BTIG Research	Buy	$16
Apr-03-20	Downgrade	Goldman	Buy → Neutral	$24 → $7
Mar-05-20	Initiated	Stifel	Buy	$21
Feb-25-20	Initiated	William Blair	Outperform
Aug-09-19	Initiated	BTIG Research	Buy	$22
Jul-16-19	Initiated	H.C. Wainwright	Buy	$21
Apr-22-19	Initiated	JP Morgan	Overweight
Apr-22-19	Initiated	Jefferies	Buy
Apr-22-19	Initiated	Goldman	Buy
Apr-22-19	Initiated	Barclays	Overweight

Show Previous Ratings

Mar-26-25 08:10AM	Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -11.00%
07:09AM	Precision BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-21-25 07:01AM	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 (Business Wire)
Mar-20-25 07:01AM	Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 (Business Wire) +6.99%
06:25PM	Loading…
Mar-19-25 06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Mar-17-25 07:01AM	Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B (Business Wire)
Feb-24-25 07:01AM	Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire) -5.06%
Feb-20-25 07:47AM	Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV (Clinical Trials Arena)
Feb-19-25 02:27PM	Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate (Benzinga) +9.71%
07:01AM	Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial (Business Wire)
Jan-29-25 07:01AM	Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs (Business Wire)
Jan-09-25 10:01AM	Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
08:00AM	iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
05:42AM	Loading…
Dec-19-24 05:42AM	Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial (Clinical Trials Arena) +11.38%
Dec-18-24 07:01AM	Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B (Business Wire) -9.83%
Nov-21-24 07:01AM	Precision BioSciences to Participate in Upcoming November Investor Conferences (Business Wire) -9.47%
Nov-15-24 07:00AM	Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B (Business Wire)
Nov-04-24 08:15AM	Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.09%
07:13AM	Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-01-24 07:43AM	Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) +5.37%
Oct-29-24 07:01AM	Precision BioSciences to Report Third Quarter Results on November 4, 2024 (Business Wire)
Oct-28-24 07:01AM	Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 (Business Wire)
Oct-24-24 04:15PM	Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress (Business Wire)
08:47AM	Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B (Business Wire)
Oct-21-24 07:01AM	Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences (Business Wire)
Oct-16-24 07:01AM	Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress (Business Wire)
Oct-03-24 07:01AM	Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire)
07:01AM	Loading…
Sep-30-24 07:01AM	Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B (Business Wire)
Sep-20-24 07:01AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 09:55AM	Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet (Zacks)
Sep-12-24 07:15AM	Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution (Business Wire)
Sep-11-24 08:50AM	Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock (Zacks)
Sep-04-24 07:01AM	Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference (Business Wire)
Sep-03-24 07:01AM	Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal (Business Wire)
Aug-28-24 09:55AM	Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade (Zacks)
Aug-12-24 04:32AM	FDA grants IND clearance for TG Therapeutics trial of multiple sclerosis treatment (Clinical Trials Arena)
Aug-09-24 07:01AM	Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis (Business Wire)
Aug-01-24 08:25AM	Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates (Zacks)
07:22AM	Precision BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
07:15AM	Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 07:01AM	Precision BioSciences to Participate in Upcoming August Investor Conferences (Business Wire)
Jul-29-24 04:15PM	Precision BioSciences to Report Second Quarter Results on August 1, 2024 (Business Wire)
Jul-08-24 07:01AM	Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit (Business Wire)
Jul-01-24 07:01AM	Precision BioSciences Announces its Addition to the Russell Microcap Index (Business Wire)
Jun-27-24 07:01AM	Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025 (Business Wire)
Jun-20-24 07:00AM	Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness (Business Wire)
Jun-05-24 07:01AM	Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress (Business Wire)
May-30-24 07:00AM	Precision BioSciences to Participate in Upcoming June Investor Conferences (Business Wire)
May-29-24 09:55AM	Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect? (Zacks)
May-17-24 07:00AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-13-24 11:53AM	DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +8.08%
07:22AM	Precision BioSciences Reports Profit From Cont. Ops. In Q1 (RTT News)
07:08AM	Precision BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:15AM	Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement (Business Wire) +6.62%
May-07-24 04:30PM	Precision BioSciences to Report First Quarter Results on May 13, 2024 (Business Wire)
08:30AM	Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECUREs Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
May-03-24 09:33AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-01-24 07:05AM	Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 (Business Wire)
Apr-16-24 04:15PM	Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics (Business Wire) -10.57%
Apr-11-24 09:55AM	Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Apr-02-24 09:55AM	Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know (Zacks) -7.61%
06:48AM	Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-27-24 11:53AM	DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:10AM	Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:07AM	Precision BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
06:45AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update (Business Wire)
Mar-20-24 04:30PM	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 (Business Wire)
Mar-19-24 07:00AM	Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy (Business Wire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.70%
Mar-06-24 08:45AM	Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency (Business Wire)
Mar-01-24 06:30AM	Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants (Business Wire) -31.24%
Feb-29-24 04:01PM	Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants (Business Wire)
09:22AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:25AM	Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength? (Zacks)
Feb-20-24 07:00AM	Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences (Business Wire) +9.28%
Feb-14-24 07:00AM	Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness (Business Wire) +7.32%
Feb-13-24 07:00AM	Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations (Business Wire)
Feb-12-24 07:00AM	Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases (Business Wire)
Feb-09-24 07:00AM	Precision BioSciences to Effect a Reverse Stock Split (Business Wire)
Jan-09-24 07:00AM	TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precisions Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases (GlobeNewswire) +10.10%
07:00AM	Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases (Business Wire)
Dec-13-23 08:20AM	Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE (Business Wire)
Dec-04-23 07:00AM	Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases (Business Wire) +5.81%
Nov-30-23 07:00AM	Precision BioSciences to Present at Hep-DART 2023 (Business Wire)
Nov-28-23 07:00AM	Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.53%
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-13-23 07:05AM	Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLDs The Liver Meeting 2023 (Business Wire) -9.45%
Nov-10-23 07:00AM	Precision BioSciences to Present at Upcoming Sidoti Conference (Business Wire)
Nov-09-23 07:00AM	Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (Business Wire)
Nov-07-23 07:54AM	Precision BioSciences Inc (DTIL) Reports Q3 2023 Financial Results (GuruFocus.com)
07:17AM	Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-01-23 07:00AM	Precision BioSciences to Report Third Quarter Results on November 7, 2023 (Business Wire) +29.63%
Oct-26-23 07:30AM	Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (Business Wire)
Oct-23-23 07:00AM	Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference (Business Wire)
Oct-12-23 08:00AM	Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (Business Wire)

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Germano Geno J	Director	Mar 25 '25	Buy	5.30	3,250	17,225	11,057	Mar 27 07:00 AM
Amoroso Michael	President and CEO	Mar 24 '25	Sale	5.56	964	5,360	109,540	Mar 25 06:00 PM
Amoroso Michael	Officer	Mar 24 '25	Proposed Sale	5.56	964	5,355		Mar 24 03:13 PM
SMITH J. JEFFERSON	Chief Research Officer	Mar 04 '25	Sale	4.91	154	756	87,805	Mar 05 07:00 PM
Scimeca Dario	General Counsel and Secretary	Mar 04 '25	Sale	4.91	272	1,336	25,000	Mar 05 07:00 PM
List Alan	Officer	Mar 05 '25	Proposed Sale	5.06	333	1,684		Mar 05 03:17 PM
SMITH J. JEFFERSON	Officer	Mar 04 '25	Proposed Sale	4.91	154	756		Mar 04 04:15 PM
Scimeca Dario	Officer	Mar 04 '25	Proposed Sale	4.91	272	1,336		Mar 04 04:13 PM
List Alan	Officer	Jan 24 '25	Proposed Sale	5.04	672	3,387		Jan 24 03:10 PM
Scimeca Dario	General Counsel and Secretary	Jan 22 '25	Sale	4.79	8,928	42,765	24,353	Jan 22 09:00 PM
Amoroso Michael	President and CEO	Jan 21 '25	Sale	4.67	36,838	172,033	107,087	Jan 22 09:00 PM
SMITH J. JEFFERSON	Chief Research Officer	Jan 22 '25	Sale	4.79	10,287	49,275	87,440	Jan 22 09:00 PM
Scimeca Dario	Officer	Jan 22 '25	Proposed Sale	4.79	8,928	42,727		Jan 22 03:14 PM
SMITH J. JEFFERSON	Officer	Jan 22 '25	Proposed Sale	4.79	10,287	49,230		Jan 22 03:13 PM
Amoroso Michael	Officer	Jan 21 '25	Proposed Sale	4.67	36,838	172,162		Jan 21 04:19 PM
Germano Geno J	Director	Dec 30 '24	Buy	4.49	3,605	16,186	7,807	Jan 02 07:00 AM
Buehler Kevin	Director	Dec 27 '24	Buy	4.88	4,320	21,082	8,712	Dec 31 07:00 AM
Kelly John Alexander	Chief Financial Officer	Dec 27 '24	Buy	4.75	2,113	10,037	40,186	Dec 31 07:00 AM
Brown Melinda	Director	Dec 26 '24	Buy	4.55	3,016	13,723	7,218	Dec 30 06:10 AM
Kelly John Alexander	Chief Financial Officer	Nov 21 '24	Buy	6.76	3,000	20,280	38,073	Nov 21 04:30 PM
Scimeca Dario	General Counsel and Secretary	Nov 02 '24	Option Exercise	0.00	1,836	0	8,557	Nov 05 07:14 PM
Scimeca Dario	General Counsel and Secretary	Nov 04 '24	Sale	8.19	588	4,816	7,969	Nov 05 07:14 PM
Amoroso Michael	President and CEO	Nov 04 '24	Sale	8.19	3,012	24,668	28,537	Nov 05 07:14 PM
Scimeca Dario	Officer	Nov 04 '24	Proposed Sale	8.19	588	4,816		Nov 04 03:51 PM
Amoroso Michael	Officer	Nov 04 '24	Proposed Sale	8.19	3,012	24,669		Nov 04 03:49 PM
Scimeca Dario	General Counsel and Secretary	Jun 07 '24	Option Exercise	0.00	301	0	6,814	Jun 11 05:13 PM
Scimeca Dario	General Counsel and Secretary	Jun 10 '24	Sale	11.79	93	1,096	6,721	Jun 11 05:13 PM
SMITH J. JEFFERSON	Chief Research Officer	Jun 10 '24	Sale	11.79	50	590	68,559	Jun 11 05:12 PM
Scimeca Dario	General Counsel and Secretary	May 02 '24	Sale	10.32	272	2,807	5,680	May 03 06:33 PM
SMITH J. JEFFERSON	Chief Research Officer	May 02 '24	Sale	10.32	154	1,589	67,613	May 03 06:32 PM
List Alan	Chief Medical Officer	May 02 '24	Sale	10.32	290	2,993	4,488	May 03 06:30 PM
Amoroso Michael	President and CEO	May 02 '24	Sale	10.32	1,526	15,748	13,772	May 03 06:29 PM
List Alan	Chief Medical Officer	Apr 30 '24	Sale	10.03	238	2,386	3,796	Apr 30 06:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DTIL

Precision Biosciences Inc

Upgrade your FINVIZ experience